This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

This book provides a comprehensive overview on the clinical issues and biology of acute promyelocytic leukemia (APL) and on the molecular mechanisms of targeted therapy with ATRA and ATO. The text covers major topics such as the pathophysiology of APL coagulopathy, biologic and clinical differences between children and adults with APL, and the role of minimal residual disease monitoring. Additionally, the book summarizes historical, current, and future treatment strategies in both adults and children, while highlighting the most recent therapeutic recommendations for relapsed disease and the evolving indications for autologous and allogeneic stem cell transplant. This volume also features chapters focusing on secondary APL and therapy, late effects, rare presentations such as APL in the elderly and during pregnancy, and rare APL variants that may represent therapeutic challenges. Written by top experts in the field, Acute Promyelocytic Leukemia: A Clinical Guide is a valuable resource for clinicians and researchers who treat and investigate this disease in children and adults.

A concise full-color review of the mechanisms of blood diseases and disorders – based on a Harvard Medical School hematology course 4 STAR DOODY'S REVIEW! "This is a superb book. Deceptively small, yet packs a wallop. The emphasis on principles instead of practice is welcome....The text is clear, concise, and surprisingly approachable for what could have been a very dense and dry discussion. I could not put this book down and read it entirely in one sitting. When was the last time anyone found a hematology textbook so riveting?"--Doody's Review Service Hematological Pathophysiology is a well-illustrated, easy-to-absorb introduction to the physiological principles underlying the regulation and function of blood cells and hemostasis, as well as the pathophysiologic mechanisms responsible for the development of blood disorders. Featuring a strong emphasis on key principles, the book covers diagnosis and management primarily within a framework of pathogenesis. Authored by world-renowned clinician/educators at Harvard Medical School, Hematological Pathophysiology features content and organization based on a hematology course offered to second year students at that school. The book is logically divided into four sections: Anemias and Disorders of the Red Blood Cell, Disorders of Hemostasis and Thrombosis, Disorders of Leukocytes, and Transfusion Medicine; it opens with an important overview of blood and hematopoietic tissues. Features Succinct, to-the-point coverage that reflects current medical education More than 200 full-color photographs and renderings of disease mechanisms and blood diseases Each chapter includes learning objectives and self-assessment questions Numerous tables and diagrams encapsulate important information Incorporates the feedback of 180 Harvard medical students who reviewed the first draft -- so you know you’re studying the most relevant material possible

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

This book discusses key aspects of childhood acute lymphoblastic leukemia (ALL), presenting the latest research on the biology and treatment of the disease and related issues. The cure rate for ALL has improved dramatically due to advances such as supportive care, treatment stratification based on relapse risk, and the optimization of treatment regimens. Gathering contributions by eminent scholars Pediatric Acute Lymphoblastic Leukemia is a valuable resource for pediatric hematologists as well as for medical students, interns, residents and fellows. It not only offers comprehensive insights, but also provides a springboard for future research.

Acute myeloid leukemia (AML) is an aggressive bone marrow cancer associated with high morbidity and mortality and most commonly affects older patient populations. In this book, the clinical presentation of acute myeloid leukemia are presented. Other chapters present the differences in the outcomes of two subtypes of core binding factor (CBF) acute myeloid leukemia (AML); examine the occurrence of the Philadelphia chromosome in AML with core binding factor leukemia; and therapeutic options of older patients with AML.